<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572454</url>
  </required_header>
  <id_info>
    <org_study_id>2012-02-012-001</org_study_id>
    <nct_id>NCT01572454</nct_id>
  </id_info>
  <brief_title>Comparison of Dexmedetomidine and Remifentanil Infusion During CABG</brief_title>
  <official_title>The Comparison of Serum Potassium Concentration, Antiarrhythmic Effect, and Myocardial Protective Effect Between Dexmedetomidine and Remifentanil Infusion in Patients Undergoing Coronary Artery Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are trying to investigate whether intraoperative dexmedetomidine infusion could decrease
      the incidence of intraoperative hypokalemia and arrhythmia, and myocardial injury in patients
      undergoing off-pump coronary artery bypass graft, and trying compare these effects with those
      of remifentanil infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alpha2-adrenergic agonist, dexmedetomidine, is recently used for sedation, analgesia or
      adjuvant to general anesthesia. Postsynaptic activation of alpha2 adrenoceptors in the
      central nervous system (CNS) inhibits sympathetic activity and thus can decrease blood
      pressure and heart rate. The blockade of sympathetic activity decrease the neuroendocrine
      stress response and may decrease the incidence of hypokalemia. The hypokalemia can increase
      the incidence of arrythmia, especially in cardiac patients. We postulated that
      dexmedetomidine could decrease the neuroendocrine stress response, thus decrease arrhythmia
      during cardiac surgery. Furthermore, dexmedetomidine have been reported to have
      cardioprotective effect with previous animal studies.

      Therefore, the aim of the present study is to investigate whether the intraoperative
      dexmedetomidine infusion can reduce the incidence of hypokalemia and arrythmia, and
      myocardial injury in subjects undergoing off-pump coronary artery bypass graft. We are also
      trying to compare these effects with those of remifentanil infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum potassium concentration</measure>
    <time_frame>at 24 hour before anesthetic induction</time_frame>
    <description>serum potassium concentration at the day before anesthetic induction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum potassium concentration</measure>
    <time_frame>1 minutes before anesthetic induction</time_frame>
    <description>1 minutes before anesthetic induction (etomidate injection)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum potassium concentration</measure>
    <time_frame>20 minutes after start of anesthetic induction</time_frame>
    <description>serum potassium concentration 20 minutes after start of anesthetic induction (at the end of anesthetic induction)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum potassium concentration</measure>
    <time_frame>2 hour after the start of anesthetic induction</time_frame>
    <description>serum potassium concentration at 2 hour after anesthetic induction (after mammary artery dissection and graft formation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum potassium concentration</measure>
    <time_frame>3 hour after start of anesthetic induction</time_frame>
    <description>serum potassium concentration at 3 hour after end of anesthetic induction (after the anastomosis of coronary graft)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas analysis results</measure>
    <time_frame>24 hour, 1 min before anesthetic induction, 20 min, 2 and 3 hour after the start of anesthetic induction</time_frame>
    <description>arterial blood gas analysis results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hypokalemia</measure>
    <time_frame>24 hour, 1 min before anesthetic induction, 20 min, 2 and 3 hour after the start of anesthetic induction</time_frame>
    <description>incidence of hypokalemia (serum K &lt; 3.5) incidence of hypokalemia (serum K &lt; 4.5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamic parameters</measure>
    <time_frame>24 hour, 1 min before anesthetic induction, 20 min, 2 and 3 hour after the start of anesthetic induction</time_frame>
    <description>hemodynamic parameters (blood pressure, heart rate, central venous pressure, cardiac output, SvO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inotropics, vasopressor requirement</measure>
    <time_frame>24 hour, 1 min before anesthetic induction, 20 min, 2 and 3 hour after the start of anesthetic induction</time_frame>
    <description>inotropics, vasopressor requirement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury marker</measure>
    <time_frame>2, 24, 48 hour after the end of surgery</time_frame>
    <description>serum concentration of CK-MB, Troponin (i)as a marker for myocaridial injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>72 hour before, during (immediate after grafting), 72 hour after surgery</time_frame>
    <description>left ventricular function determined by Tei index, ejection fraction of preoperative, intraoperative, postoperative echocardiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Coronary Artery Bypass Graft</condition>
  <condition>Hypokalemia</condition>
  <condition>Cardiac Arrhythmia</condition>
  <condition>Dexmedetomidine</condition>
  <condition>Remifentanil</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine infusion</intervention_name>
    <description>Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <other_name>Dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil infusion</intervention_name>
    <description>Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery</description>
    <arm_group_label>Remifentanil group</arm_group_label>
    <other_name>Remifentanil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Those undergoing off-pump coronary artery bypass graft during March, 2012 ~ February,
             2013 in Samsung Medical Center

          -  Age between 20 and 70 yrs old

        Exclusion Criteria:

          -  Any patients with plasma aldosterone, or glucocorticoid disorder including primary
             hyperaldosteronism, renovascular hypertension, rennin-secreting tumor, salt-wasting
             renal disease, Cushing syndrome

          -  Patients with recent exogenous steroid administration or previous diuretics therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun Sung Cho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won Ho Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Tak Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>December 24, 2013</last_update_submitted>
  <last_update_submitted_qc>December 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Hyun Sung Cho</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>coronary artery bypass graft</keyword>
  <keyword>hypokalemia</keyword>
  <keyword>cardiac arrhythmia</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>remifentanil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Hypokalemia</mesh_term>
    <mesh_term>Potassium Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

